Barrons
30 Sept 2026, 11:42 UTC · 1h ago
Verdict
Source says Downgrade to Sell. We score MRNA −0.80 across one claim.
Score confirms the headline.
Downgrade to Sell
Rating stated in the headline
−0.80strongly bearish
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Citi downgraded Moderna from Hold to Sell, citing insufficient data on its cancer vaccine, instimeran autogene, to justify its valuation.
NewCiti just downgraded it
So whatA downgrade from a major prime broker often triggers immediate institutional outflows and a contraction of the forward P/E multiple.
More negative than 94% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More negative than 84% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
5h ago
—
MRNA hasn't traded since this ran. Last close $203.46 (Sep 29); the reaction starts at the next open.
MRNA chart →
